FDA OKs Celgene’s fedratinib for myelofibrosis

Under Priority Review status, FDA approves Celgene’s (CELG +0.6%) Inrebic (fedratinib) for the treatment of a bone marrow disorder called intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocytopenia) myelofibrosis.

Fedratinib inhibits a tyrosine kinase enzyme called JAK2. It will compete with Incyte’s (INCY +0.8%) JAK1/2 inhibitor Jakafi (ruxolitinib), approved in the U.S. in 2011 for myelofibrosis and 2014 for polycythemia vera.

Related ticker: Bristol-Myers Squibb (BMY +1.1%)

https://seekingalpha.com/news/3492604-fda-oks-celgenes-fedratinib-myelofibrosis